Generic drug approvals, pricing and competition
Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo …
Mexico’s Cofepris has established an abbreviated registration pathway recognising ANVISA evaluations, with a 45-business-day resolution ceiling — accelerating market entry for manufacturers already cleared in Brazil.
Brazil’s health regulator has approved five new semaglutide injection pens for diabetes treatment, intensifying competition against Novo Nordisk as the molecule’s patent expired in March 2026.
You must be logged in to post a comment.